Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines
- PMID: 38360356
- DOI: 10.1016/j.jinf.2024.106119
Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Raj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, Joyce S. Plested, Anand Parekh, Drew Gorinson, Rongman Cai, Soham Mahato, Anthony M. Marchese, and Lisa M. Dunkle are the employees and stockholders of Novavax, Inc. Lou Fries serves as a contractor and is a stockholder of Novavax Inc. Pradhipa Ramanathan (P.R.), Lidwina Carissa Aurelia (L.C.A.), Kevin John Selva (K.J.S.), and Amy W. Chung (A.W.C.) are the employees of the Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity. A.W.C. received grant funding from NHMRC, MRFF, and NIH. P.R., L.C.A., and K.J.S. declare no conflicts/disclosure of information.
Update of
-
Altered IgG4 Antibody Response to Repeated mRNA versus Protein COVID Vaccines.medRxiv [Preprint]. 2024 Jan 18:2024.01.17.24301374. doi: 10.1101/2024.01.17.24301374. medRxiv. 2024. Update in: J Infect. 2024 Mar;88(3):106119. doi: 10.1016/j.jinf.2024.106119. PMID: 38293205 Free PMC article. Updated. Preprint.
References
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous